TNF and COVID-19: In a case series study treatment of severe COVID-19 patients with infliximab (IFX), an anti-TNF antibody showed a rapid and temporary decrease in pro-inflammatory mediators such as IL-6 and other inflammatory markers (lactate dehydrogenase and C-reactive protein) along with clinical improvement in 6 of 7 infected patients.